PERIOGARD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Periogard, and what generic alternatives are available?
Periogard is a drug marketed by Colgate Palmolive Co and Colgate-palmolive Co and is included in two NDAs.
The generic ingredient in PERIOGARD is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Periogard
A generic version of PERIOGARD was approved as chlorhexidine gluconate by BECTON DICKINSON on October 24th, 1989.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PERIOGARD?
- What are the global sales for PERIOGARD?
- What is Average Wholesale Price for PERIOGARD?
Summary for PERIOGARD
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 8 |
| Drug Prices: | Drug price information for PERIOGARD |
| DailyMed Link: | PERIOGARD at DailyMed |
Recent Clinical Trials for PERIOGARD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Colgate Palmolive | PHASE3 |
| Colgate Palmolive | Phase 2 |
| University of North Carolina, Chapel Hill | Phase 2 |
Pharmacology for PERIOGARD
| Physiological Effect | Decreased Cell Wall Integrity |
US Patents and Regulatory Information for PERIOGARD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colgate Palmolive Co | PERIOGARD | chlorhexidine gluconate | SOLUTION;DENTAL | 073695-001 | Jan 14, 1994 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Colgate-palmolive Co | PERIOGARD | chlorhexidine gluconate | SOLUTION;DENTAL | 203212-001 | Jan 28, 2016 | AT | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
